Free Trial
CVE:DMT

Small Pharma (DMT) Stock Price, News & Analysis

Small Pharma logo
C$0.15 -0.01 (-6.25%)
As of 10/20/2023

About Small Pharma Stock (CVE:DMT)

Key Stats

Today's Range
C$0.15
▼
C$0.16
50-Day Range
C$0.15
▼
C$0.15
52-Week Range
C$0.06
▼
C$0.22
Volume
1.89 million shs
Average Volume
296,159 shs
Market Capitalization
C$50.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc.

Receive DMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DMT Stock News Headlines

Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock ahead of October 20. His system has spotted at least seven of the top 10 performers every year since 2016, including all ten in the 2022 bear market and every member of the Magnificent Seven before their run higher. Now Chaikin's Power Gauge is turning bullish on an under-the-radar company tied to next-generation AI data centers built under Executive Order 14363, technology he says uses 99 percent less electricity and space while offering far greater computing power.tc pixel
See More Headlines

DMT Stock Analysis - Frequently Asked Questions

Small Pharma's stock was trading at C$0.15 on January 1st, 2026. Since then, DMT stock has increased by 0.0% and is now trading at C$0.15.

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
CVE:DMT
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
C($0.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$19.31 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-116.90%
Return on Assets
-66.00%

Debt

Debt-to-Equity Ratio
5.95
Current Ratio
2.63
Quick Ratio
6.28

Sales & Book Value

Annual Sales
-C$1.16 thousand
Price / Sales
-43,343.80
Cash Flow
C$0.13 per share
Price / Cash Flow
1.13
Book Value
C$0.03 per share
Price / Book
5.00

Miscellaneous

Outstanding Shares
335,770,000
Free Float
N/A
Market Cap
C$50.37 million
Optionable
Not Optionable
Beta
0.86
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (CVE:DMT) was last updated on 10/20/2023 by MarketBeat.com Staff.
From Our Partners